Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
about
Microneedle-based drug and vaccine delivery via nanoporous microneedle arraysMicroneedle enhanced delivery of cosmeceutically relevant peptides in human skin.Recovery of skin barrier after stratum corneum removal by microdermabrasion.Microneedles for drug and vaccine deliveryThe emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation.Diclofenac delays micropore closure following microneedle treatment in human subjectsDiclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation.Novel engineered systems for oral, mucosal and transdermal drug delivery.Skin permeabilization for transdermal drug delivery: recent advances and future prospects.Characterization of microchannels created by metal microneedles: formation and closure.Transdermal drug delivery: feasibility for treatment of superficial bone stress fractures.Biomedical applications of microneedles in therapeutics: recent advancements and implications in drug delivery.Repeat application of microneedles does not alter skin appearance or barrier function and causes no measurable disturbance of serum biomarkers of infection, inflammation or immunity in mice in vivo.Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatment.Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery.
P2860
Q28085656-CB166335-EDB2-4283-892B-90CFC8DEC851Q35208322-07CD8387-FA90-4FE9-9F2F-36D6376B71D1Q35577226-FE5F4D8B-CB99-4E57-AF0C-9B578735FCC3Q36164749-303193B6-6FD8-4D2C-84D3-8A04AFABF75EQ36587156-AD0B8B7C-6063-4693-BB92-063C6745C88CQ37051274-63C5F379-D5EE-40A3-9A1D-705A784C461CQ37173681-2D70B636-842A-49F7-805F-2FC0C14A0FA0Q37359303-63A5E095-78B7-4577-8A5E-1E65428CD36FQ38122744-8A12642D-BCC8-4BF5-9440-34F5D9547B20Q38176047-9F4C6074-0221-4508-9B7A-807B262141CFQ38254574-DF5A8692-E9A7-4EE4-B837-7A5697EA770FQ38583019-BCC4AA32-56B4-4CBB-A7A6-C940B11BAEC8Q38630763-38D7225B-D36E-43CC-A7DE-32798F9E6D83Q40223873-E8B982FC-D625-4ACC-9872-7988AF0DACCBQ41518982-EA0582DC-9FD0-45CA-8710-84CABC89A440Q41964832-3DD1C6F6-9412-4231-A72A-0C1FB442023DQ43082308-C27E3400-1943-4426-BE75-92FB971C0CCD
P2860
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
@en
type
label
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
@en
prefLabel
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
@en
P2093
P2860
P1476
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
@en
P2093
Audra L Stinchcomb
Charles D Loftin
Kalpana S Paudel
Nicole K Brogden
Stan L Banks
P2860
P304
P356
10.1007/S11095-011-0372-2
P577
2011-02-08T00:00:00Z